# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k183517   
B. Purpose for Submission: New device   
C. Measurand: Ammonia   
D. Type of Test: Quantitative, enzymatic   
E. Applicant: Roche Diagnostics Operations (RDO)   
F. Proprietary and Established Names: Ammonia II

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1065 Ammonia test system

2. Classification: Class I, reserved

3. Product code: JIF

4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s): Refer to Indications for use below.

2. Indication(s) for use:

The Ammonia II assay is an enzymatic in vitro test for the quantitative determination of ammonia in human plasma on Roche/Hitachi cobas c systems.

Ammonia measurements are used in the diagnosis and treatment of severe liver disorders, such as cirrhosis, hepatitis, and Reye's syndrome.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Roche cobas c 501 Analyzer

# I. Device Description:

The reagent consists of 2 components R1 and R3. R1 contains N,N-bias (2-hydroxyethy)- glycine buffer: $3 0 0 \mathrm { m m o l / L }$ , $\mathsf { p H } 8 . 3$ ; GLDH(microbial): $\geq 1 6 . 7 \mu \mathrm { k a t / L }$ , a detergent and a preservative. R3 contains GLDH(microbial) ${ \ge } 5 . 0 \ \mu \mathrm { k a t / L }$ , 2-oxoglutarate $7 8 \mathrm { m m o l / L }$ , $\mathrm { N A D P H } \geq 1 . 3$ mmol in a non-reactive buffer.

# J. Substantial Equivalence Information:

1. Predicate device name(s): SYNCHRON Systems Ammonia Reagent

2. Predicate 510(k) number(s): k003196

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate DeviceAmmonia II (k183517)</td><td rowspan=1 colspan=1>Predicate deviceSYNCHRON SystemsAmmonia Reagent (k003196)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Quantitative measurement ofammonia in human plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Test principle</td><td rowspan=1 colspan=1>Biochromatic Rate</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Prepackaged for use on anautomated system</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate DeviceAmmonia II (k183517)</td><td rowspan=1 colspan=1>Predicate deviceSYNCHRON SystemsAmmonia Reagent (k003196)</td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>10-1000 μmol/L(17-1703 µg/dL)</td><td rowspan=1 colspan=1>9-1000 μmol/L(16 - 1700 µg/dL)</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>K2- and K3-EDTA plasma</td><td rowspan=1 colspan=1>Sodium heparin and EDTAplasma</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A3: Evaluation of Precision Performance of Quantitative Measurement Methods, 3rd Edition.

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures; A Statistical Approach, $2 ^ { \mathrm { n d } }$ Edition.

CLSI EP07-A2: Interference Testing in Clinical Chemistry, $2 ^ { \mathrm { n d } }$ Edition.

CLSI EP17-A2: Protocols for Determination of Limits of Detection and Limits of Quantitation, $2 ^ { \mathrm { n d } }$ Edition.

# L. Test Principle:

The Ammonia II assay is an enzymatic method, with glutamate dehydrogenase. Glutamate dehydrogenase (GLDH) catalyzes the reductive amination of 2‑oxoglutarate with $\mathrm { N H 4 + }$ and NADPH to form glutamate and ${ \mathrm { N A D P + } }$ . The concentration of the ${ \mathrm { N A D P + } }$ formed is directly proportional to the ammonia concentration. It is determined by measuring the decrease in absorbance. Ammonia concentrations can be reported in conventional $\mathrm { ( \mu g / d L ) }$ or International System $\mathrm { \langle \mu m o l / L \rangle }$ units, the conversion factor is: $\mathrm { \mu m o l { / L } } \times 1 . 7 0 3 = \mathrm { \mu g / d L }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision measurements were conducted to evaluate repeatability (within-run precision) and the intermediate precision (within-laboratory precision) according to the CLSI EP05-A3 guideline. The testing was performed over 21 days, with two separate runs per day and two replicate measurements per run resulting in a total n of 84. Two levels of control and 5 human plasma samples were evaluated. The results are summarized in the tables below:

Repeatability Summary:   

<table><tr><td rowspan=1 colspan=1>samples</td><td rowspan=1 colspan=1>Mean (μmol/L)</td><td rowspan=1 colspan=1>SD (μmol/L)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>AEC- Control N</td><td rowspan=1 colspan=1>66.6</td><td rowspan=1 colspan=1>1.40</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>AEC-Control A</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 1</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 2</td><td rowspan=1 colspan=1>57.7</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 3</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 4</td><td rowspan=1 colspan=1>492</td><td rowspan=1 colspan=1>4.12</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 5</td><td rowspan=1 colspan=1>868</td><td rowspan=1 colspan=1>9.54</td><td rowspan=1 colspan=1>1.1</td></tr></table>

Intermediate Precision:

<table><tr><td rowspan=1 colspan=1>samples</td><td rowspan=1 colspan=1>Mean (μmol/L)</td><td rowspan=1 colspan=1>SD (μmol/L)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>AEC-Control N</td><td rowspan=1 colspan=1>67.9</td><td rowspan=1 colspan=1>1.61</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>AEC-Control P</td><td rowspan=1 colspan=1>243</td><td rowspan=1 colspan=1>4.26</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 1</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 2</td><td rowspan=1 colspan=1>57.7</td><td rowspan=1 colspan=1>1.72</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 3</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>1.92</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 4</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>6.30</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Human Plasma 5</td><td rowspan=1 colspan=1>853</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>1.5</td></tr></table>

# b. Linearity/assay reportable range:

Linearity was evaluated in accordance with the CLSI EP-06A guideline. 18 levels were prepared using a human plasma samples pool with ammonia concentration above the upper measuring range. The mean of 3 replicates was used to evaluate linearity at each level using 3 reagent lots. The range of samples tested was 0-1089 $\mu \mathrm { m o l / L }$ .

Linear regression of one representative lot produced the following result:

$$
\mathbf { y } = 1 . 0 0 3 \mathrm { x } - 2 . 1 9 ~ \mathrm { r } ^ { 2 } = 0 . 9 9 9 9
$$

The results of the linearity study support the claimed measuring range of 10-1000 $\mu \mathrm { m o l / L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

This method has been standardized against an internal gravimetrically prepared primary standard.

# d. Detection limit:

The limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ) of the Ammonia II assay were evaluated in accordance with the CLSI EP17-A2 guideline.

LoB study was performed with one analyte-free sample tested over 3 days using three reagent lots in 10-fold determination for a total 60 measurements per lot, on one cobas c 501 analyzer. Data analysis was based on determination of the $9 5 ^ { \mathrm { t h } }$ percentile of the 60 measured values. The LoB was determined to be $1 . 8 0 \ \mu \mathrm { m o l / L }$ .

The LoD study was performed with five low analyte samples which were tested over 3 days using 3 reagents lots in two-fold determination in 6 runs on one cobas c 501 analyzer for a total of 60 measurements per lot. The LoD was determined as the lowest amount of analytes that can be detected with a $9 5 \%$ probability. The LoD was determined to be $3 . 4 6 ~ \mu \mathrm { m o l / L }$ .

The LoQ study a low-level sample set was prepared by diluting 7 human samples. These 7 human plasma samples were tested for 5 days, one run per day in 5 replicates per sample, with three reagent lots on one cobas 501 analyzer instrument. LoQ was determined to be $9 . 3 6 \ \mu \mathrm { m o l / L }$ based on total precision $( \leq 2 0 )$ .

The LoB, LoD and LoQ results are summarized below:   

<table><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>1.80 μmol/L</td><td rowspan=1 colspan=1>3.46 μmol/L</td><td rowspan=1 colspan=1>9.36 μmol/L</td></tr></table>

# e. Analytical specificity:

Interference was evaluated according to the CLSI EP07-A2 guideline. The sponsor defined interference as bias exceeding $\pm 5 ~ \mu \mathrm { m o l / L }$ for samples with ammonia levels ${ \leq } 5 0 ~ \mathrm { \mu m o l / L }$ or $10 \%$ for samples with ammonia levels ${ > } 5 0 \ \mathrm { m m o l / L }$ , where bias is calculated as the difference in results between the control sample (without interferent) and the test sample (contains the interferent).

The concentration in the table below represents the highest concentration of the potential interferent tested that did not cause interference.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Test concentration</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200 mg/L</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>1000 mg/L</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>77.2 g/L</td></tr><tr><td rowspan=1 colspan=1>Ampicillin-Na</td><td rowspan=1 colspan=1>1000 mg/L</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>300 mg/L</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (conjugated)</td><td rowspan=1 colspan=1>64 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (unconjugated)</td><td rowspan=1 colspan=1>68 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>2500 mg/L</td></tr><tr><td rowspan=1 colspan=1>Cyanocobalamin</td><td rowspan=1 colspan=1>0.001 mg/L</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>5 mg/L</td></tr><tr><td rowspan=1 colspan=1>Doxycycline</td><td rowspan=1 colspan=1>50 mg/L</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>114 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5000 U</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500 mg/L</td></tr><tr><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>71.4 g/L</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>20 mg/L</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>764 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Methyldopa + 1.5</td><td rowspan=1 colspan=1>20 mg/L</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>200 mg/L</td></tr><tr><td rowspan=1 colspan=1>N-Acetylcysteine</td><td rowspan=1 colspan=1>1660 mg/L</td></tr><tr><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>500 mg/L</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>400 mg/L</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>60 mg/L</td></tr><tr><td rowspan=1 colspan=1>Sulfapyridin</td><td rowspan=1 colspan=1>300 mg/L</td></tr><tr><td rowspan=1 colspan=1>Sulfasalazin</td><td rowspan=1 colspan=1>300 mg/L</td></tr><tr><td rowspan=1 colspan=1>Temozolomid</td><td rowspan=1 colspan=1>13 mg/L</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>15 mg/L</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>100 mg/L</td></tr></table>

f. Assay cut-off:

Not applicable.

2. Comparison studies:

# a. Method comparison with predicate device:

112 human plasma samples were tested in singlicate with the SYNCHRON Systems Ammonia Reagent on Beckmann Synchron $\mathrm { D x C } 8 0 0$ (predicate device) and the Ammonia II reagent on cobas c 501 (candidate device). The samples tested had concentrations between 10.8 and $9 9 6 \mu \mathrm { m o l / L }$ .

The results obtained by linear regression analysis are summarized below:

$$
\mathbf { y } = 1 . 0 0 1 \mathrm { x } - 1 . 9 0 \mu \mathrm { m o l / L } , \mathrm { r } = 1 . 0 0 0
$$

$b$ . Matrix comparison:

To demonstrate equivalence between K2-EDTA and K3-EDTA anticoagulants, 52 matched plasma samples were obtained and tested using the Ammonia II reagent on the cobas c 501. The linear regression is summarized below:

$$
\mathbf { y } = 1 . 0 0 5 \mathrm { x } - 1 . 3 9 ~ \mathrm { \mu m o l / L } , \mathrm { r } = 1 . 0 0 0
$$

The study results support the sponsor’s claim that human K2-EDTA and K3-EDTA plasma are acceptable sample types to be used with this assay.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: The following are the reference ranges from published literature: Females $1 1 { - } 5 1 ~ \mathrm { \mu m o l / L }$ (18.7‑86.9 μg/dL) Males $1 6 { - } 6 0 ~ \mathrm { \mu m o l / L } ~ ( 2 7 . 2 { - } 1 0 2 ~ \mu g / d \mathrm { L } )$

The sponsor recommends that each laboratory should investigate the transferability of the expected values to its own patient population and, if necessary, establish their own reference ranges.

Reference: Da Fonseca-Wollheim F. Deamidation of glutamine by increased plasma $\gamma \mathrm { . }$ -glutamyl transferase is a source of rapid ammonia formation in blood and plasma specimens. Clin Chem 1990;36:1479-1482.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.